Targeting mutant huntingtin for the development of disease-modifying therapy.

Abstract:

:Huntington's disease (HD) is a progressive and fatal neurodegenerative disease, and the most common inherited CAG repeat disorder. A polyglutamine expansion in the N-terminus of the huntingtin protein (HTT) leads to protein misfolding and downstream pathogenic processes culminating in widespread functional impairment and neurodegeneration in the striatum, cortex and other brain areas. To date, only symptomatic treatments are available that address motor, psychiatric and cognitive deficits. Here we review recent strategies for developing disease-modifying therapies designed to limit or abolish the pathogenic activities of the primary molecular target in HD, the mutant HTT protein itself.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Appl T,Kaltenbach L,Lo DC,Terstappen GC

doi

10.1016/j.drudis.2012.06.017

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

1217-23

issue

21-22

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(12)00233-4

journal_volume

17

pub_type

杂志文章,评审
  • Molecular perspectives on solid-state phase transformation and chemical reactivity of drugs: metoclopramide as an example.

    abstract::Here, I provide an overview of the solid-state characteristics, phase transformations and chemical reactions of metoclopramide hydrochloride monohydrate (MCP HCl H2O). Three unique techniques, including thermoanalytical methods, one-step simultaneous differential scanning calorimetry (DSC) and Fourier transform infrar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.10.001

    authors: Lin SY

    更新日期:2015-02-01 00:00:00

  • The multiple therapeutic applications of miRNAs for bone regenerative medicine.

    abstract::With the aging of the general population, there is an increasing need for bone defect repair, prompting the development of reliable alternatives to autologous bone grafting, without the usually associated major drawbacks (i.e., limited volume and severe postoperative pain). Given the crucial role that miRNAs appear to...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.007

    authors: Scimeca JC,Verron E

    更新日期:2017-07-01 00:00:00

  • Strategies for drug discovery by targeting sulfation pathways.

    abstract::Posttranslational modifications of proteins such as phosphorylation have been recognized as pivotal modulators of biological activity in healthy and diseased tissues. Sulfation is a key posttranslational modification the role of which in physiology and pathology is only now becoming appreciated. Whereas phosphorylatio...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(04)03261-1

    authors: Hemmerich S,Verdugo D,Rath VL

    更新日期:2004-11-15 00:00:00

  • Modulating TNF-alpha signaling with natural products.

    abstract::Natural products have been, and continue to be, a major source of pharmacologically active substances from which drugs can be developed. Currently, tumor necrosis factor-alpha (TNF-alpha) inhibitors from natural origins are being advanced for the treatment of inflammatory disorders. Elevated TNF-alpha synthesis has be...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.06.002

    authors: Paul AT,Gohil VM,Bhutani KK

    更新日期:2006-08-01 00:00:00

  • Graphene-based nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineering.

    abstract::Here, we discuss the biomedical applications of graphene-based nanomaterials (GBNs). We examine graphene and its various derivatives, including graphene, graphene oxides (GOs), reduced graphene oxides (rGOs), graphene quantum dots (GQDs), and graphene composites, and discuss their unique properties related to their bi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.002

    authors: Zhao H,Ding R,Zhao X,Li Y,Qu L,Pei H,Yildirimer L,Wu Z,Zhang W

    更新日期:2017-09-01 00:00:00

  • New insight into unexpected bone formation by denosumab.

    abstract::Denosumab (Dmab) was the first monoclonal antibody (mAb) approved for the treatment of osteoporosis. It blocks the receptor activator for nuclear factor κB ligand (RANKL) and acts as a potent antiresorptive agent. In contrast to classic antiresorptive agents, Dmab treatment leads to a progressive increase in bone mass...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.09.001

    authors: Wang L,Huang B,Chen X,Su J

    更新日期:2020-09-09 00:00:00

  • Gastrointestinal patch systems for oral drug delivery.

    abstract::Gastrointestinal patch systems with integrated multifunctions could surmount the challenges associated with conventional drug delivery. Several gastrointestinal patch systems provide bioadhesion, drug protection and unidirectional release. This combination of function could improve the overall oral bioavailability of ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03489-6

    authors: Tao SL,Desai TA

    更新日期:2005-07-01 00:00:00

  • Building relationships between academia and the pharmaceutical industry.

    abstract::'The climate is perfect for a proactive search for partners between industry and academia.' ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01543-9

    authors: Dean P

    更新日期:2000-09-01 00:00:00

  • Advanced nanovehicles for cancer management.

    abstract::Over the past decade, together with the improvement of traditional cancer treatments, conveniently designed (with respect to their size, shape, main material, and coating) and specifically targeted nanovehicles have been developed. Nano-sized carriers can be functionalized to recognize key structures expressed in canc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.06.020

    authors: Saenz del Burgo L,Pedraz JL,Orive G

    更新日期:2014-10-01 00:00:00

  • Gastric bypass surgery mimetic approaches.

    abstract::Gastric bypass surgery is effectively a polypharmacological approach for treatment of obesity, type 2 diabetes and nonalcoholic steatohepatitis (NASH). The gastric bypass mimetic approaches reviewed are fixed-dose combinatorial pharmacological approaches. There are two key concepts incorporated into these gastric bypa...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.009

    authors: Boettcher BR

    更新日期:2017-08-01 00:00:00

  • Cancer therapy via modulation of micro RNA levels: a promising future.

    abstract::Micro RNAs (miRNAs) are a class of naturally occurring ∼ 22 nt long non-coding small RNA molecules that regulate the expression of a wide range of genes involved in development, growth, proliferation and apoptosis. miRNAs are evolutionarily conserved from plants to animals, and they regulate and fine-tune a diverse ar...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.07.003

    authors: Kota SK,Balasubramanian S

    更新日期:2010-09-01 00:00:00

  • Pharmaceutical patents: reconciling the human right to health with the incentive to invent.

    abstract::In developed countries that protect core aspects of the fundamental human right to the highest attainable standard of health, how does that right intersect with intellectual property rights? Here, the human rights implication of providing access to all cancer drugs recommended by experts in a developed country is cons...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.04.009

    authors: Khachigian LM

    更新日期:2020-07-01 00:00:00

  • Immunoinformatics: current trends and future directions.

    abstract::Immunoinformatics has recently emerged as a critical field for accelerating immunology research. Although still an evolving process, computational models now play instrumental roles, not only in directing the selection of key experiments, but also in the formulation of new testable hypotheses through detailed analysis...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.04.001

    authors: Tong JC,Ren EC

    更新日期:2009-07-01 00:00:00

  • Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins.

    abstract::Cervical cancer is the fourth most common cancer among women worldwide and its development is mainly associated with human papillomavirus infection, a highly sexually transmissible virus. The expression of E6 and E7 viral oncoproteins deregulates cell repairing mechanisms through impairment of tumor suppressor protein...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.07.011

    authors: Almeida AM,Queiroz JA,Sousa F,Sousa Â

    更新日期:2019-10-01 00:00:00

  • Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors.

    abstract::Telomerase is a ribonucleic reverse transcriptase enzyme that uses an integral RNA component as a template to add tandem telomeric DNA repeats, TTAGGG, at the 3' end of the chromosomes. 85-90% of human tumors and their derived cell lines predominantly express high levels of telomerase, therefore contributing to cancer...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.05.015

    authors: Saraswati AP,Relitti N,Brindisi M,Gemma S,Zisterer D,Butini S,Campiani G

    更新日期:2019-07-01 00:00:00

  • Homologous recombination in human iPS and ES cells for use in gene correction therapy.

    abstract::The emergence of induced pluripotent stem (iPS) cell technology has shifted gene correction therapy toward reality. Crucial issues are ensuring the safety of using iPS cell technology in patients and discovering how best to transfer genetically manipulated iPS cells back into patients. One key issue that has hindered ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.01.006

    authors: Nakayama M

    更新日期:2010-03-01 00:00:00

  • Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems.

    abstract::Quercetin is reported to have numerous pharmacological actions, including antidiabetic, anti-inflammatory and anticancer activities. The main mechanism responsible for its pharmacological activities is its ability to quench reactive oxygen species (ROS) and, hence, decrease the oxidative stress responsible for the dev...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.11.001

    authors: Khursheed R,Singh SK,Wadhwa S,Gulati M,Awasthi A

    更新日期:2020-01-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)02006-2

    authors: Westwell AD

    更新日期:2001-11-15 00:00:00

  • Updating molecular properties during early drug discovery.

    abstract::Current multiparameter optimization (MPO) strategies make use of few experimental physicochemical descriptors (i.e., solubility at physiological pH and lipophilicity in the octanol/water system). Here, we show how new trends in drug discovery (i.e., large and flexible molecules for 'difficult' targets) call for the in...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2016.11.017

    authors: Caron G,Ermondi G

    更新日期:2017-06-01 00:00:00

  • Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

    abstract::Cancer is the second highest cause of death worldwide. Several therapeutic approaches, such as conventional chemotherapy, antibodies and small molecule inhibitors and nanotherapeutics have been employed in battling cancer. Amongst them, nanotheranostics is an example of successful personalized medicine bearing dual ro...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.08.009

    authors: Nabil G,Bhise K,Sau S,Atef M,El-Banna HA,Iyer AK

    更新日期:2019-02-01 00:00:00

  • Current status and future prospects of toxicogenomics in drug discovery.

    abstract::In drug discovery and development (DDD), the efficacy, safety and cost of new chemical entities are the main concerns of the pharmaceutical industry. Continuously updated and stricter recommendations imposed by regulatory authorities result in greater challenges being faced by the industry. Reliable high-throughput te...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2013.11.001

    authors: Khan SR,Baghdasarian A,Fahlman RP,Michail K,Siraki AG

    更新日期:2014-05-01 00:00:00

  • Monitor: molecules and profiles.

    abstract::Monitor provides an insight into the latest developments in drug discovery through brief synopses of recent presentations and publications together with expert commentaries on the latest technologies. There are two sections: Molecules summarizes the chemistry and the pharmacological significance and biological relevan...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(00)01533-6

    authors: Lloyd AW

    更新日期:2000-08-01 00:00:00

  • Atomic force microscopy and drug discovery.

    abstract::Atomic force microscopy is being used ever more widely in biological imaging, because of its unique ability to provide structural information at the single molecule level and under near-physiological conditions. Detailed topographic images of potential drug targets, such as proteins and DNA, have been produced, and th...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)02905-2

    authors: Edwardson JM,Henderson RM

    更新日期:2004-01-15 00:00:00

  • What is precise pathophysiology in development of hypertension in pregnancy? Precision medicine requires precise physiology and pathophysiology.

    abstract::It is widely accepted that placental ischemia is central in the evolution of hypertension in pregnancy. Many studies and reviews have targeted placental ischemia to explain mechanisms for initiating pregnancy hypertension. The placenta is rich in blood vessels, which are the basis for developing placental ischemia. Ho...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.10.021

    authors: Gao Q,Tang J,Li N,Liu B,Zhang M,Sun M,Xu Z

    更新日期:2018-02-01 00:00:00

  • Top 100 bestselling drugs represent an arena struggling for new FDA approvals: drug age as an efficiency indicator.

    abstract::We analyzed a list of the top 100 bestselling drugs as a struggling market for new FDA approvals. Using the time from drug approval by the FDA as a measure of drug age, our analysis showed that the top 100 bestselling drugs are getting older. This reflects the stalled launch of new drugs into the market during recent ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2015.06.015

    authors: Polanski J,Bogocz J,Tkocz A

    更新日期:2015-11-01 00:00:00

  • How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease.

    abstract::The current understanding of the pathology that underlies pulmonary vascular and right ventricular remodeling in pulmonary hypertension is discussed. Although recent studies underscored the importance of intima and media remodeling and, for the first time, the relevance of perivascular inflammation, much is needed to ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.05.022

    authors: Tuder RM

    更新日期:2014-08-01 00:00:00

  • New pharmacological approaches to atrial fibrillation.

    abstract::Atrial fibrillation (AF) is the most common cardiac arrhythmia facing physicians, afflicting 13% of men and 11% of women over 85 years of age. Epidemiological studies estimate that there are ≥ 11 million AF sufferers in the seven major economies and that its prevalence will increase two- to threefold over the next 50 ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2012.02.007

    authors: Milnes JT,Madge DJ,Ford JW

    更新日期:2012-07-01 00:00:00

  • Compound high-quality criteria: a new vision to guide the development of drugs, current situation.

    abstract::For several decades, the pharmaceutical industry has suffered due to major issues such as reductions of the number of FDA approved drugs and biologics. Several analyses have been highlighted that the 'druglikeness' is one of the strategies to improve succeed rates of screening such as, for instance, high-throughput sc...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.01.005

    authors: Mignani S,Huber S,Tomás H,Rodrigues J,Majoral JP

    更新日期:2016-04-01 00:00:00

  • Novel procedure for rapid pharmacokinetic screening of discovery compounds in rats.

    abstract::In therapeutic areas aimed at developing an orally administered drug, the pharmacokinetic profile of a drug candidate after oral administration in vivo is pivotal in evaluating its success. This can be done by monitoring the plasma concentration versus time after dosing and calculating the area under the curve (AUC). ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(98)01299-9

    authors: Cox KA,Dunn-Meynell K,Korfmacher WA,Broske L,Nomeir AA,Lin CC,Cayen MN,Barr WH

    更新日期:1999-05-01 00:00:00

  • Diagnostic challenges for multiplexed protein microarrays.

    abstract::Multiplexed protein analysis using planar microarrays or microbeads is growing in popularity for simultaneous assays of antibodies, cytokines, allergens, drugs and hormones. However, this new assay format presents several new operational issues for the clinical laboratory, such as the quality control of protein-microa...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.09.010

    authors: Master SR,Bierl C,Kricka LJ

    更新日期:2006-11-01 00:00:00